Keros Therapeutics Inc (KROS) - Net Assets
Based on the latest financial reports, Keros Therapeutics Inc (KROS) has net assets worth $703.58 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($742.78 Million) and total liabilities ($39.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read total liabilities of Keros Therapeutics Inc for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $703.58 Million |
| % of Total Assets | 94.72% |
| Annual Growth Rate | 88.43% |
| 5-Year Change | 118.38% |
| 10-Year Change | N/A |
| Growth Volatility | 1749.41 |
Keros Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how Keros Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore KROS asset base for the complete picture of this company's asset base.
Annual Net Assets for Keros Therapeutics Inc (2018–2024)
The table below shows the annual net assets of Keros Therapeutics Inc from 2018 to 2024. For live valuation and market cap data, see KROS stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $571.55 Million | +72.04% |
| 2023-12-31 | $332.21 Million | +19.75% |
| 2022-12-31 | $277.42 Million | +14.08% |
| 2021-12-31 | $243.17 Million | -7.09% |
| 2020-12-31 | $261.72 Million | +4701.34% |
| 2019-12-31 | $5.45 Million | -57.27% |
| 2018-12-31 | $12.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Keros Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56146500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.00% |
| Other Components | $1.14 Billion | 199.51% |
| Total Equity | $571.55 Million | 100.00% |
Keros Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Keros Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
$358.59 Million |
|
CMC Magnetics Corp
TW:2323
|
$358.65 Million |
|
Hangzhou IECHO Science & Technology Co. Ltd. A
SHG:688092
|
$358.66 Million |
|
Infortrend Technology Inc
TW:2495
|
$358.96 Million |
|
Cogeco Inc.
TO:CGO
|
$358.52 Million |
|
Cohen Dev
TA:CDEV
|
$358.50 Million |
|
Guangdong Tengen Industrial Group C
SHE:003003
|
$358.42 Million |
|
Gladstone Investment Corporation 8.00% Notes due 2028
NASDAQ:GAINL
|
$358.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Keros Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 332,213,000 to 571,553,000, a change of 239,340,000 (72.0%).
- Net loss of 187,353,000 reduced equity.
- New share issuances of 380,134,000 increased equity.
- Other factors increased equity by 46,559,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-187.35 Million | -32.78% |
| Share Issuances | $380.13 Million | +66.51% |
| Other Changes | $46.56 Million | +8.15% |
| Total Change | $- | 72.04% |
Book Value vs Market Value Analysis
This analysis compares Keros Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 8.19x to 0.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $1.44 | $11.77 | x |
| 2019-12-31 | $0.61 | $11.77 | x |
| 2020-12-31 | $16.88 | $11.77 | x |
| 2021-12-31 | $10.42 | $11.77 | x |
| 2022-12-31 | $10.99 | $11.77 | x |
| 2023-12-31 | $11.28 | $11.77 | x |
| 2024-12-31 | $15.27 | $11.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Keros Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.78%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5277.55%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.08x
- Recent ROE (-32.78%) is above the historical average (-56.42%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -10.46% | -13.35% | 0.36x | 2.15x | $-2.61 Million |
| 2019 | -226.45% | -123.44% | 0.91x | 2.01x | $-12.89 Million |
| 2020 | -17.33% | -1814.44% | 0.01x | 1.03x | $-71.53 Million |
| 2021 | -24.16% | -292.26% | 0.08x | 1.05x | $-83.06 Million |
| 2022 | -37.73% | -523.40% | 0.07x | 1.11x | $-132.42 Million |
| 2023 | -46.05% | -101319.21% | 0.00x | 1.11x | $-186.21 Million |
| 2024 | -32.78% | -5277.55% | 0.01x | 1.08x | $-244.51 Million |
Industry Comparison
This section compares Keros Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $146,753,554
- Average return on equity (ROE) among peers: -18.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Keros Therapeutics Inc (KROS) | $703.58 Million | -10.46% | 0.06x | $358.59 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $119.10 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $-4.24 Million | 0.00% | 0.00x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $181.98 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $547.68 Million | -11.16% | 0.30x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $-6.52 Million | 0.00% | 0.00x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.81 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $400.41 Million | -53.94% | 0.47x | $3.81 Billion |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias… Read more